OKYO Pharma LimitedOKYO
Price$1.34

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2025
Net Income -$4.7MTTM through 31 Mar 2025
Free Cash Flow -$1.8MTTM through 31 Mar 2025

Margins

Current

Returns

84.8%ROE
-128.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio0.40x
Net Debt-$1.6Mnet cash position
Cash & Equivalents$4.6M

Quality Metrics

Piotroski F-Score4 / 9

Multi-Year Trend

Diluted EPS
'20'21'22
FY2022: $-0.01

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Ophthalmology Drug Development$0
View details

Advancing urcosimod into a planned 150-patient Phase 2b/3 clinical trial for neuropathic corneal pain in 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.